美股A股
StockGist

Repligen Corporation

RGENNASDAQ · Healthcare · Medical - Instruments & Supplies
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europ…
$162.78-2.99%
报价 2026-11-16
市值
$10.41B
EV
$9.82B
PE (TTM)
233.1x
预期 PE (FY2026)
78.5x
52 周区间距高点 -16.3%
$102.87$194.57

筛选结果

pipeline · 2026-11-16
Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool

爆发潜力

2026-11-16
未命中✗ 收入线✗ EPS 线
财年收入倍数EPSPE
FY+22027-121.3x2.04 → 2.66(1.3x)61.3
FY+32028-121.5x2.04 → 3.42(1.7x)47.5

毛利率 51% · TTM 收入 $806M · 基数 EPS 2.04(调整后)

研究结论

还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。

去生成基本面报告 →

历史股价

加载中…

事件

0 条 · 随区间与图例筛选

该区间内无事件。

同行对比

FMP 同行列表 · 2026-05-16
公司市值今日预期营收增速毛利率PEEV/EBITDAP/FCF池
RGENRepligen Corporation$10.41B-3.0%+15.8%53.1%233.1x56.2x87.9x
CRLCharles River Laboratories International, Inc.$16.08B-0.7%-1.4%36.2%–91.3x46.6x
BAXBaxter International Inc.$13.21B-1.0%+5.8%33.4%–25.5x13.6x
DVADaVita Inc.$10.96B-0.2%+4.9%30.9%17.5x9.3x8.5x
AVTRAvantor, Inc.$10.38B-1.4%+2.2%31.5%31.7x15.4x24.5x
BIOBio-Rad Laboratories, Inc.$9.69B-1.7%+0.4%51.9%9.4x9.6x29.4x
GMEDGlobus Medical, Inc.$9.34B-2.3%+6.5%67.4%21.9x13.9x12.3x
ATRAptarGroup, Inc.$9.08B+0.1%+8.7%27.8%22.0x11.1x25.3x
STVNStevanato Group S.p.A.$4.24B-1.7%–29.1%–––
同行中位数––+4.9%32.4%21.9x13.9x24.5x

研究全文

L2 基本面 memo

尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。

财务报表

Metric
2026-06-30
Q2 2026
2026-03-31
Q1 2026
2025-12-31
Q4 2025
2025-09-30
Q3 2025
2025-06-30
Q2 2025
2025-03-31
Q1 2025
2024-12-31
Q4 2024
2024-09-30
Q3 2024
Revenue$204.1M$194.3M$197.9M$188.8M$182.4M$169.2M$167.5M$154.9M
Gross Margin53.1%50.7%47.2%53.2%50%53.6%23.2%50%
Operating Margin5.8%9.3%9.4%8.9%7.6%3.9%-21.8%-5.1%
Net Income$5M$8.3M$13.3M$14.9M$14.9M$5.8M$-33.9M$-654,000
Diluted EPS0.090.150.230.260.260.1-0.60.32
Operating Cash Flow$32.8M$28.3M$25.7M$48.1M$28.6M$15M$39.2M$49.3M

研究材料